T-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design
|
|
- Vincent Gregory
- 6 years ago
- Views:
Transcription
1 T-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design James A. Bolognese, Cytel Nitin Patel, Cytel Yevgen Tymofyeyef, Merck Inna Perevozskaya, Wyeth Jeff Palmer, Millenium Acknowledgement: Vipul Suru and Patrick Tai of Cytel provided valuable programming support
2 OUTLINE T-statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design JSM2008 Presentation by Nitin Patel, et al. - Comparison based on true underlying 4-parameter logistic (4PL) dose-response curves Review summary of findings JSM2009 Current Presentation - Comparison based on true underlying NON-4PL dose-response curves Bayesian 4PL adaptive design T-Statistic Up&Down adaptive design Simulation Spec s Findings Summary / Conclusions / Recommendations 8/17/09 Confidential Cytel
3 Simulation Comparison of Bayesian & T-Stat Dose-Adaptive Designs (Patel N, et al. JSM2008) Concluding Remarks Based on simulated data from 4-parameter logistic dose response models: The two methods are comparable in terms of their performance criteria Bayesian method Better MSE of estimate of mean response at target dose can be much better when the number of possible doses is large relative to sample size an important advantage is ability to use informative priors T-Stat implementation for an actual trial is easier Adaptive randomization can be implemented by switching between pre-generated randomization lists Frequentist methods are familiar to trial statisticians, clinicians, and managers Future work study non-4-parameter logistic dose-response curves 3 3
4 Bayesian Design Uses 4-parameter logistic model as parametric approximation of response curve Assumes flat (non-informative) prior distribution for parameters of logistic curve model for mean response and σ 2 4 4
5 Bayesian Adaptive Allocation 1. Specify dose assignments to subjects in first cohort 2. Use responses of all previous cohorts to compute posterior distribution 3. Compute an effectiveness criterion for each possible dose if assigned to next subject. 4. Use effectiveness criterion to assign doses to subjects in next cohort 5. Repeat 2 nd to 4 th steps until the trial sample size is reached 5 5
6 Effectiveness Criterion The expected decrease in variance of the mean response at the target dose is estimated for each possible dose assignment using the most recent posterior distribution. Doses are assigned to subjects in the next cohort with probability proportional to the square root of this expected decrease 6 6
7 T-statistic method of Ivanova, et al. (Stat in Med, 2008) At each look the next cohort is randomized with a fixed number of subjects on placebo and the remaining subjects at the dose level of the previous cohort or one level above or below it. The decision of whether to stay at the previous level, go up, or go down is made by computing a t-statistic defined by: Where n 1 is the number of subjects assigned to placebo so far with mean response and n j is the total (cumulative) number of subjects assigned so far to the dose level of the previous cohort with mean response. S is the pooled standard deviation estimate, and D is the target level of response (difference from placebo). 7 7
8 T-Stat Design Up&Down Rule If - ψ < T j < ψ assign next cohort dose that is the same as the previous cohort If T j - ψ, assign dose to next cohort that is one level above that of the previous cohort (unless previous dose was highest, in which case assign same dose) If T j ψ assign dose to next cohort that is one level below that of the previous cohort (unless previous dose was lowest, in which case assign same dose) For our simulations we used ψ =
9 Seven Dose Response Curves (Y-axis response is difference from placebo) DR_1 Linear DR_2 Umbrella DR_3 Sigmoid Emax DR_4 Emax DR_5 Emax low DR_6 Explicit DR_7 Null Case Target Response 9 9
10 Seven Dose Response Curves (Y-axis response is difference from placebo) Target Response DR_1 Linear DR_2 Umbrella DR_3 Sigmoid Emax DR_4 Emax DR_5 Emax low DR_6 Explicit DR_7 Null Case 10 10
11 Simulation Scenarios Error SD = 1.3 (Effect Sizes of Targets: ~0.4, ~0.7) Sample sizes (drug:placebo~2:1 and 3:1) = 135, 200, 320 Number of equally sized cohorts: 12 to 32, depending on sample size Target doses = Dose with mean response 0.5 and 0.9 (each run separately) Active drug patients in first cohort of each simulation assigned Dose replications of trials for each scenario 11 11
12 Performance Criteria 1. Power to reject null hypothesis of no difference from placebo to demonstrate proof-of-concept (trend test using linear regression) 2. Probability of selecting dose that is at or near target dose. Dose with mean closest to target level of response, selected using isotonic regression fit to response data 3. Mean Square Error and Bias in estimation of mean response at the target dose (maximum likelihood estimates from isotonic regression fit) 4. Number of Patients assigned to dose with est. mean nearest target and next nearest (i.e., at or adjacent to target dose) 12 12
13 Power (%), 0.5 target, Doses 2,4,6,8 design Sample size: Placebo size: Design: Bayes T-Stat Bayes T-Stat Bayes T-Stat Linear SigmoidEmax Emax Explicit Umbrella Emax Low Null Case * * * difference>2 * alpha-level inflated somewhat; should be 2.5% 13
14 % at or near 0.5 target, Doses 2,4,6,8 design Sample size: Placebo size: Design: Bayes T-Stat Bayes T-Stat Bayes T-Stat Linear SigmoidEmax Emax Explicit difference>2 Umbrella Emax Low Null Case
15 #Patients allocated to doses for 0.5 target, Doses 2,4,6,8 design (Total N=135) Design dose_0 dose_2 dose_4 dose_6 dose_8 Bayesian Linear T-Stat Bayesian Sigmoid T-Stat Bayesian Emax T-Stat Bayesian Explicit T-Stat Bayesian Umbrella T-Stat Bayesian EmaxLow T-Stat Bayesian Null Case T-Stat more at target dose, Target Dose Bolded 15
16 Power (%), 0.9 target, Doses 1 to 8 design Sample size Placebo size Bayes T-Stat Bayes T-Stat Bayes T-Stat Linear SigmoidEmax Emax Explicit Umbrella Emax Low Null Case 4.1* * * 3.4* difference>2 * alpha-level inflated somewhat; should be 2.5% 16
17 % at or near 0.9 target, Doses 1 to 8 design Sample size Placebo size Design Bayes T-Stat Bayes T-Stat Bayes T-Stat Linear SigmoidEmax Emax Explicit Umbrella Emax Low Null Case difference>2 17
18 #Patients allocated to doses for 0.9 target, Doses 1 to 8 design (Total N=135) Design D0 D1 D2 D3 D4 D5 D6 D7 D8 Bayesian Linear T-Stat Bayesian Sigmoid T-Stat Bayesian Emax T-Stat Bayesian Explicit T-Stat Bayesian Umbrella T-Stat Bayesian EmaxLow T-Stat Bayesian Null Case T-Stat more at target dose, Target Dose Bolded
19 Main Conclusions (T=T-Stat; B=Bayesian) Target: Doses: 0.5 2,4,6, to ,4,6, to 8 Power % at or near target B & T generally similar; T-Stat somewhat inflated type I error for 4 doses B & T generally similar T-Stat mostly better Each better in some cases; most gen. similar Bias T-Stat better at Dose 8 T-Stat better at Dose 8 & target dose T-Stat better at Dose 8 & target dose T-Stat better at Doses 7 & 8, & at target dose MSE T-Stat better at Dose 8 T-Stat better at Dose 8 & target dose No clear winner #@target dose T-Stat generally assigns more than Bayesian B & T generally similar 19 19
20 Concluding Remarks Our simulations show that the two adaptive methods demonstrate useful performance criteria Bayesian 4-parameter logistic Design Better if model is closer to S-shaped or linear Better to model response across dose-range an important advantage could be its ability to use informative priors T-Stat Up&Down Design Implementation for an actual trial is easier Better properties at extremes of dose-range Better properties at doses with targeted level of response Choice of Design driven by particular study objectives and span of potential true underlying dose-response curves assumed
21 References 1. Patel N, Bolognese J, Perevozskaya I. (2008 Joint Statistics Meetings, Denver, CO, USA) Comparing a Bayesian approach with a frequentist t-statistic method in adaptive dose finding trials Ivanova A, Bolognese J, and Perevozskaya I. (2008) Adaptive design based on t-statistic for dose-response trials. Statistics in Medicine, 27:
22 BACK-UP SLIDES FOLLOW THIS ONE 8/17/09 Confidential Cytel
23 Single dose-adaptive design can replace typical PoC and PIIa dose-ranging trials Tradi&onal Phase II Program 2N* 5N 4N PoC (Ib/IIa) (High Dose vs. Placebo) Dose Finding Defini;ve Dose Response (if needed) Phase III Phase II with Dose Adap&ve PoC Trial 3 4N^ 4N PoC (Some Doses vs. Placebo) Defini;ve Dose Response (if needed) Phase III *N = # subjects/group for desired precision in PoC trial ^ 2N, if fu&lity realized Replace 2 trials with 1 4N fewer subjects; less &me
24 Motivation Merck and Cytel collaboration over past three years to develop CytelSim, a soft ware tool for design of adaptive dose-finding clinical trials Two methods for PhII dose finding trials Bayesian method 4 parameter logistic model for mean dose response By Scott Berry for Cytel Frequentist method T-Statistic to adapt dose allocation By Ivanova, et al. (2008)
25 Four parameter logistic curve Where µ is the mean response at dose d β, δ, θ, τ are the four parameters of the logistic curve β=minimum, β+δ=maximum θ=inflection point (ED50) τ=slope parameter 25 25
26 Seven Dose Response Curves (Y-axis response is difference from placebo) DR_1 Linear DR_2 Umbrella DR_3 Sigmoid Emax DR_4 Emax DR_5 Emax low DR_6 Explicit DR_7 Null Case Target Response dose closest to target 4- doses 8- doses 2,4,6,8 1 to 8 26 DR_ ID <2 < <2 <1 6 >8 >8 7 26
27 Seven Dose Response Curves (Y-axis response is difference from placebo) Target Response DR_1 Linear DR_2 Umbrella DR_3 Sigmoid Emax DR_4 Emax DR_5 Emax low DR_6 Explicit DR_7 Null Case dose closest to target 4- doses 8- doses 2,4,6,8 1 to 8 DR_ ID ,8 4, >8 > >8 >
28 Simulation Results Two cases summarized on following slides (sometimes for representative sample size) Design with Doses 2,4,6,8 targeted to response = 0.5 Design with Doses 1 to 8 targeted to response = 0.9 By Sample size or for N=135 Cohort sizes & pbo:active ratios similar so averaged Other cases summarized in Main Conclusions above Design with Doses 1 to 8 targeted to response = 0.5 Design with Doses 2,4,6,8 targeted to response =
29 Bias for 0.5 target case, Doses 2,4,6,8 design Placebo size 45 Sample size 135 Design dose_0 dose_2 dose_4 dose_6 dose_8 Bayesian Linear T-Stat ratio(b/ttest) Bayesian Sigmoid T-Stat Emax ratio(b/ttest) Bayesian Emax T-Stat ratio(b/ttest) Bayesian Explicit T-Stat ratio(b/ttest) bias>0.1, Target Dose Bolded 29
30 Bias for 0.5 target case, Doses 2,4,6,8 design Placebo size 45 Sample size 135 Design dose_0 dose_2 dose_4 dose_6 dose_8 Bayesian Um T-Stat brella ratio(b/ttest) Bayesian Emax T-Stat Low ratio(b/ttest) Bayesian Null T-Stat Case ratio(b/ttest) bias>0.1, Target Dose Bolded 30
31 MSE for 0.5 target case, Doses 2,4,6,8 design Placebo size 45 Total Sample size 135 Design dose_0 dose_2 dose_4 dose_6 dose_8 Bayesian Linear T-Stat ratio(b/ttest) Bayesian Sigmoid T-Stat Emax ratio(b/ttest) Bayesian Emax T-Stat ratio(b/ttest) Bayesian Explicit T-Stat ratio(b/ttest) MSE>0.1, Target Dose Bolded
32 MSE for 0.5 target case, Doses 2,4,6,8 design Placebo size 45 Total Sample size 135 Design dose_0 dose_2 dose_4 dose_6 dose_8 Bayesian Um T-Stat brella ratio(b/ttest) Bayesian Emax T-Stat Low ratio(b/ttest) Bayesian Null T-Stat Case ratio(b/ttest) MSE>0.1, Target Dose Bolded 32
33 Bias for 0.9 target case, Doses 1 to 8 design Placebo N=45 Total N=135 Design D0 D1 D2 D3 D4 D5 D6 D7 D8 Bayesian Linear T-Stat ratio(b/t) Bayesian Sigmoid T-Stat ratio(b/t) Bayesian Emax T-Stat ratio(b/t) Bayesian Explicit T-Stat ratio(b/t) bias>0.1, Target Dose Bolded 33
34 Bias for 0.9 target case, Doses 1 to 8 design Placebo N=45 Total N=135 Design D0 D1 D2 D3 D4 D5 D6 D7 D8 Bayesian Umbrela T-Stat ratio(b/t) Bayesian EmxLow T-Stat ratio(b/t) Bayesian Null T-Stat ratio(b/t) bias>0.1, Target Dose Bolded 34
35 MSE for 0.9 target case, Doses 1 to 8 design Placebo size 45 Total Sample size 135 Design D0 D1 D2 D3 D4 D5 D6 D7 D8 Bayesian Linear T-Stat ratio(b/t) Bayesian Sigmoid T-Stat ratio(b/t) Bayesian Emax T-Stat ratio(b/t) Bayesian Explicit T-Stat ratio(b/t) bias>0.1, Target Dose Bolded 35
36 MSE for 0.9 target case, Doses 1 to 8 design Placebo size 45 Total Sample size 135 Design D0 D1 D2 D3 D4 D5 D6 D7 D8 Bayesian Umbrela T-Stat ratio(b/t) Bayesian EmxLow T-Stat ratio(b/t) Bayesian Null T-Stat ratio(b/t) MSE>0.1, Target Dose Bolded 36
An Introduction to Bayesian Statistics
An Introduction to Bayesian Statistics Robert Weiss Department of Biostatistics UCLA Fielding School of Public Health robweiss@ucla.edu Sept 2015 Robert Weiss (UCLA) An Introduction to Bayesian Statistics
More informationRolling Dose Studies
PhRMA PISC Working Group on Rolling Dose Studies Results, Conclusions and Recommendations PISC Project Leaders Teleconference, July 07, 2006 Outline Goals and scope Evaluating DF methods: simulation study
More informationST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods
(10) Frequentist Properties of Bayesian Methods Calibrated Bayes So far we have discussed Bayesian methods as being separate from the frequentist approach However, in many cases methods with frequentist
More informationInnovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials
Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials Amit Roy, Bristol-Myers Squibb on behalf of the PhRMA Adaptive Dose Finding Studies Working Group PharmaEd Resources Conference
More informationMS&E 226: Small Data
MS&E 226: Small Data Lecture 10: Introduction to inference (v2) Ramesh Johari ramesh.johari@stanford.edu 1 / 17 What is inference? 2 / 17 Where did our data come from? Recall our sample is: Y, the vector
More informationEvaluating Adaptive Dose Finding Designs and Methods
Evaluating Adaptive Dose Finding Designs and Methods Amit Roy Bristol-Myers Squibb IIR Conference on Clinical Trial Design Princeton, NJ September 12-14, 2006 Acknowledgments: Adaptive Dose Finding Studies
More informationEffective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.
Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development Pantelis Vlachos Cytel Inc, Geneva Acknowledgement Joint work with Giacomo Mordenti, Grünenthal Virginie
More informationDesign for Targeted Therapies: Statistical Considerations
Design for Targeted Therapies: Statistical Considerations J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center Outline Premise General Review of Statistical Designs
More informationTreatment effect estimates adjusted for small-study effects via a limit meta-analysis
Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Gerta Rücker 1, James Carpenter 12, Guido Schwarzer 1 1 Institute of Medical Biometry and Medical Informatics, University
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationDrug Supply for Adaptive Trials
Drug Supply for Adaptive Trials Nitin R Patel Co-founder and Chairman, Cytel Inc. Outline Challenge of planning drug supply for adaptive trials Combining statistical design simulation with drug supply
More informationClinical trial design issues and options for the study of rare diseases
Clinical trial design issues and options for the study of rare diseases November 19, 2018 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is
More informationA Case Study: Two-sample categorical data
A Case Study: Two-sample categorical data Patrick Breheny January 31 Patrick Breheny BST 701: Bayesian Modeling in Biostatistics 1/43 Introduction Model specification Continuous vs. mixture priors Choice
More informationDecision Making in Confirmatory Multipopulation Tailoring Trials
Biopharmaceutical Applied Statistics Symposium (BASS) XX 6-Nov-2013, Orlando, FL Decision Making in Confirmatory Multipopulation Tailoring Trials Brian A. Millen, Ph.D. Acknowledgments Alex Dmitrienko
More informationBayesian hierarchical modelling
Bayesian hierarchical modelling Matthew Schofield Department of Mathematics and Statistics, University of Otago Bayesian hierarchical modelling Slide 1 What is a statistical model? A statistical model:
More informationAnalysis of left-censored multiplex immunoassay data: A unified approach
1 / 41 Analysis of left-censored multiplex immunoassay data: A unified approach Elizabeth G. Hill Medical University of South Carolina Elizabeth H. Slate Florida State University FSU Department of Statistics
More informationBayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity. Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi
Bayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi 1 Outline Introduction Methods EWOC EWOC-PH Modifications to account for
More informationCity, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Burmeister, E. and Aitken, L. M. (2012). Sample size: How many is enough?. Australian Critical Care, 25(4), pp. 271-274.
More information(b) empirical power. IV: blinded IV: unblinded Regr: blinded Regr: unblinded α. empirical power
Supplementary Information for: Using instrumental variables to disentangle treatment and placebo effects in blinded and unblinded randomized clinical trials influenced by unmeasured confounders by Elias
More informationLec 02: Estimation & Hypothesis Testing in Animal Ecology
Lec 02: Estimation & Hypothesis Testing in Animal Ecology Parameter Estimation from Samples Samples We typically observe systems incompletely, i.e., we sample according to a designed protocol. We then
More informationBayesian Joint Modelling of Benefit and Risk in Drug Development
Bayesian Joint Modelling of Benefit and Risk in Drug Development EFSPI/PSDM Safety Statistics Meeting Leiden 2017 Disclosure is an employee and shareholder of GSK Data presented is based on human research
More informationUsing mixture priors for robust inference: application in Bayesian dose escalation trials
Using mixture priors for robust inference: application in Bayesian dose escalation trials Astrid Jullion, Beat Neuenschwander, Daniel Lorand BAYES2014, London, 11 June 2014 Agenda Dose escalation in oncology
More informationLecture Outline Biost 517 Applied Biostatistics I. Statistical Goals of Studies Role of Statistical Inference
Lecture Outline Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Statistical Inference Role of Statistical Inference Hierarchy of Experimental
More informationDynamic borrowing of historical data: Performance and comparison of existing methods based on a case study
Introduction Methods Simulations Discussion Dynamic borrowing of historical data: Performance and comparison of existing methods based on a case study D. Dejardin 1, P. Delmar 1, K. Patel 1, C. Warne 1,
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationUnderstandable Statistics
Understandable Statistics correlated to the Advanced Placement Program Course Description for Statistics Prepared for Alabama CC2 6/2003 2003 Understandable Statistics 2003 correlated to the Advanced Placement
More informationHypothesis Testing. Richard S. Balkin, Ph.D., LPC-S, NCC
Hypothesis Testing Richard S. Balkin, Ph.D., LPC-S, NCC Overview When we have questions about the effect of a treatment or intervention or wish to compare groups, we use hypothesis testing Parametric statistics
More informationComparability Study of Online and Paper and Pencil Tests Using Modified Internally and Externally Matched Criteria
Comparability Study of Online and Paper and Pencil Tests Using Modified Internally and Externally Matched Criteria Thakur Karkee Measurement Incorporated Dong-In Kim CTB/McGraw-Hill Kevin Fatica CTB/McGraw-Hill
More informationUnderstanding Statistics for Research Staff!
Statistics for Dummies? Understanding Statistics for Research Staff! Those of us who DO the research, but not the statistics. Rachel Enriquez, RN PhD Epidemiologist Why do we do Clinical Research? Epidemiology
More informationNEW METHODS FOR SENSITIVITY TESTS OF EXPLOSIVE DEVICES
NEW METHODS FOR SENSITIVITY TESTS OF EXPLOSIVE DEVICES Amit Teller 1, David M. Steinberg 2, Lina Teper 1, Rotem Rozenblum 2, Liran Mendel 2, and Mordechai Jaeger 2 1 RAFAEL, POB 2250, Haifa, 3102102, Israel
More informationFundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationBayesian Latent Subgroup Design for Basket Trials
Bayesian Latent Subgroup Design for Basket Trials Yiyi Chu Department of Biostatistics The University of Texas School of Public Health July 30, 2017 Outline Introduction Bayesian latent subgroup (BLAST)
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationIntroduction. We can make a prediction about Y i based on X i by setting a threshold value T, and predicting Y i = 1 when X i > T.
Diagnostic Tests 1 Introduction Suppose we have a quantitative measurement X i on experimental or observed units i = 1,..., n, and a characteristic Y i = 0 or Y i = 1 (e.g. case/control status). The measurement
More informationWeek 8 Hour 1: More on polynomial fits. The AIC. Hour 2: Dummy Variables what are they? An NHL Example. Hour 3: Interactions. The stepwise method.
Week 8 Hour 1: More on polynomial fits. The AIC Hour 2: Dummy Variables what are they? An NHL Example Hour 3: Interactions. The stepwise method. Stat 302 Notes. Week 8, Hour 1, Page 1 / 34 Human growth
More informationDesigning a Bayesian randomised controlled trial in osteosarcoma. How to incorporate historical data?
Designing a Bayesian randomised controlled trial in osteosarcoma: How to incorporate historical data? C. Brard, L.V Hampson, M-C Le Deley, G. Le Teuff SCT - Montreal, May 18th 2016 Brard et al. Designing
More informationInferential Statistics
Inferential Statistics and t - tests ScWk 242 Session 9 Slides Inferential Statistics Ø Inferential statistics are used to test hypotheses about the relationship between the independent and the dependent
More informationStatistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute
Statistical Challenges for Novel Technologies Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute ISCTM 2016 Autumn Conference, Philadelphia, PA 27 September
More informationSelection of Linking Items
Selection of Linking Items Subset of items that maximally reflect the scale information function Denote the scale information as Linear programming solver (in R, lp_solve 5.5) min(y) Subject to θ, θs,
More informationBiostatistical modelling in genomics for clinical cancer studies
This work was supported by Entente Cordiale Cancer Research Bursaries Biostatistical modelling in genomics for clinical cancer studies Philippe Broët JE 2492 Faculté de Médecine Paris-Sud In collaboration
More informationSmall-area estimation of mental illness prevalence for schools
Small-area estimation of mental illness prevalence for schools Fan Li 1 Alan Zaslavsky 2 1 Department of Statistical Science Duke University 2 Department of Health Care Policy Harvard Medical School March
More informationMEA DISCUSSION PAPERS
Inference Problems under a Special Form of Heteroskedasticity Helmut Farbmacher, Heinrich Kögel 03-2015 MEA DISCUSSION PAPERS mea Amalienstr. 33_D-80799 Munich_Phone+49 89 38602-355_Fax +49 89 38602-390_www.mea.mpisoc.mpg.de
More informationEvidence Based Medicine
Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed
More informationExposure-response in the presence of confounding
Exposure-response in the presence of confounding Jonathan L. French, ScD Metrum Research Group LLC May 3, 2016 c 2016 Metrum Research Group LLC TICTS, Durham, NC, 2016 May 3, 2016 1 / 24 Outline 1 Introduction
More informationInvestigating the robustness of the nonparametric Levene test with more than two groups
Psicológica (2014), 35, 361-383. Investigating the robustness of the nonparametric Levene test with more than two groups David W. Nordstokke * and S. Mitchell Colp University of Calgary, Canada Testing
More informationCatherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1
Welch et al. BMC Medical Research Methodology (2018) 18:89 https://doi.org/10.1186/s12874-018-0548-0 RESEARCH ARTICLE Open Access Does pattern mixture modelling reduce bias due to informative attrition
More informationA web application for conducting the continual reassessment method
A web application for conducting the continual reassessment method Nolan A. Wages, PhD Biostatistics Shared Resource University of Virginia Cancer Center March 3, 2017 Dose-finding Setting Initial Safety
More informationResearch Methods in Forest Sciences: Learning Diary. Yoko Lu December Research process
Research Methods in Forest Sciences: Learning Diary Yoko Lu 285122 9 December 2016 1. Research process It is important to pursue and apply knowledge and understand the world under both natural and social
More informationSmall Sample Bayesian Factor Analysis. PhUSE 2014 Paper SP03 Dirk Heerwegh
Small Sample Bayesian Factor Analysis PhUSE 2014 Paper SP03 Dirk Heerwegh Overview Factor analysis Maximum likelihood Bayes Simulation Studies Design Results Conclusions Factor Analysis (FA) Explain correlation
More informationStepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality
Week 9 Hour 3 Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Stat 302 Notes. Week 9, Hour 3, Page 1 / 39 Stepwise Now that we've introduced interactions,
More informationNo Large Differences Among Centers in a Multi-Center Neurosurgical Clinical Trial
No Large Differences Among Centers in a Multi-Center Neurosurgical Clinical Trial Emine O Bayman 1,2, K Chaloner 2,3, BJ Hindman 1 and MM Todd 1 1:Anesthesia, 2:Biostatistics, 3: Stat and Actuarial Sc,
More informationBayesian integration in sensorimotor learning
Bayesian integration in sensorimotor learning Introduction Learning new motor skills Variability in sensors and task Tennis: Velocity of ball Not all are equally probable over time Increased uncertainty:
More informationPsychology Research Process
Psychology Research Process Logical Processes Induction Observation/Association/Using Correlation Trying to assess, through observation of a large group/sample, what is associated with what? Examples:
More informationPsychology Research Process
Psychology Research Process Logical Processes Induction Observation/Association/Using Correlation Trying to assess, through observation of a large group/sample, what is associated with what? Examples:
More informationIntroduction to Bayesian Analysis 1
Biostats VHM 801/802 Courses Fall 2005, Atlantic Veterinary College, PEI Henrik Stryhn Introduction to Bayesian Analysis 1 Little known outside the statistical science, there exist two different approaches
More informationA Brief Introduction to Bayesian Statistics
A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon
More informationJSM Survey Research Methods Section
Methods and Issues in Trimming Extreme Weights in Sample Surveys Frank Potter and Yuhong Zheng Mathematica Policy Research, P.O. Box 393, Princeton, NJ 08543 Abstract In survey sampling practice, unequal
More informationThe statistical significance filter leads to overconfident expectations of replicability
The statistical significance filter leads to overconfident expectations of replicability Shravan Vasishth and Andrew Gelman Universität Potsdam, Germany Columbia University, USA Contact: vasishth@uni-potsdam.de
More informationSheila Barron Statistics Outreach Center 2/8/2011
Sheila Barron Statistics Outreach Center 2/8/2011 What is Power? When conducting a research study using a statistical hypothesis test, power is the probability of getting statistical significance when
More informationComputer Age Statistical Inference. Algorithms, Evidence, and Data Science. BRADLEY EFRON Stanford University, California
Computer Age Statistical Inference Algorithms, Evidence, and Data Science BRADLEY EFRON Stanford University, California TREVOR HASTIE Stanford University, California ggf CAMBRIDGE UNIVERSITY PRESS Preface
More informationA Bayesian Nonparametric Model Fit statistic of Item Response Models
A Bayesian Nonparametric Model Fit statistic of Item Response Models Purpose As more and more states move to use the computer adaptive test for their assessments, item response theory (IRT) has been widely
More informationComputerized Mastery Testing
Computerized Mastery Testing With Nonequivalent Testlets Kathleen Sheehan and Charles Lewis Educational Testing Service A procedure for determining the effect of testlet nonequivalence on the operating
More informationOptimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents
Optimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents Maria-Athina Altzerinakou1,2,3 and Xavier Paoletti3,1,2 1. CESP OncoStat, Inserm, Villejuif,
More informationPSYCHOLOGY 300B (A01) One-sample t test. n = d = ρ 1 ρ 0 δ = d (n 1) d
PSYCHOLOGY 300B (A01) Assignment 3 January 4, 019 σ M = σ N z = M µ σ M d = M 1 M s p d = µ 1 µ 0 σ M = µ +σ M (z) Independent-samples t test One-sample t test n = δ δ = d n d d = µ 1 µ σ δ = d n n = δ
More informationMethod Comparison for Interrater Reliability of an Image Processing Technique in Epilepsy Subjects
22nd International Congress on Modelling and Simulation, Hobart, Tasmania, Australia, 3 to 8 December 2017 mssanz.org.au/modsim2017 Method Comparison for Interrater Reliability of an Image Processing Technique
More informationDichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods
Merrill and McClure Trials (2015) 16:523 DOI 1186/s13063-015-1044-z TRIALS RESEARCH Open Access Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of
More informationMCQ Course in Pediatrics Al Yamamah Hospital June Dr M A Maleque Molla, FRCP, FRCPCH
MCQ Course in Pediatrics Al Yamamah Hospital 10-11 June Dr M A Maleque Molla, FRCP, FRCPCH Q1. Following statements are true in the steps of evidence based medicine except ; a) Convert the need for information
More informationPractical Bayesian Design and Analysis for Drug and Device Clinical Trials
Practical Bayesian Design and Analysis for Drug and Device Clinical Trials p. 1/2 Practical Bayesian Design and Analysis for Drug and Device Clinical Trials Brian P. Hobbs Plan B Advisor: Bradley P. Carlin
More informationSimple Linear Regression the model, estimation and testing
Simple Linear Regression the model, estimation and testing Lecture No. 05 Example 1 A production manager has compared the dexterity test scores of five assembly-line employees with their hourly productivity.
More informationSample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome
Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome Stephen Burgess July 10, 2013 Abstract Background: Sample size calculations are an
More information3. Fixed-sample Clinical Trial Design
3. Fixed-sample Clinical Trial Design Review of course organization 1. Scientific Setting 1.1 Introduction and overview 1.2 Phases of investigation 1.3 Case Study 2. From scientific setting to statistical
More informationPOPULATION PHARMACOKINETICS. Population Pharmacokinetics. Definition 11/8/2012. Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development.
/8/202 POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug
More informationMCAS Equating Research Report: An Investigation of FCIP-1, FCIP-2, and Stocking and. Lord Equating Methods 1,2
MCAS Equating Research Report: An Investigation of FCIP-1, FCIP-2, and Stocking and Lord Equating Methods 1,2 Lisa A. Keller, Ronald K. Hambleton, Pauline Parker, Jenna Copella University of Massachusetts
More informationUnit 1 Exploring and Understanding Data
Unit 1 Exploring and Understanding Data Area Principle Bar Chart Boxplot Conditional Distribution Dotplot Empirical Rule Five Number Summary Frequency Distribution Frequency Polygon Histogram Interquartile
More informationSHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms
SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms Claudia Filozof, MD PhD Executive Medical Director Covance Challenges in Clinical Development in NASH
More informationBayesian additive decision trees of biomarker by treatment interactions for predictive biomarkers detection and subgroup identification
Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarkers detection and subgroup identification Wei Zheng Sanofi-Aventis US Comprehend Info and Tech Talk outlines
More information11/18/2013. Correlational Research. Correlational Designs. Why Use a Correlational Design? CORRELATIONAL RESEARCH STUDIES
Correlational Research Correlational Designs Correlational research is used to describe the relationship between two or more naturally occurring variables. Is age related to political conservativism? Are
More informationBayesian performance
Bayesian performance In this section we will study the statistical properties of Bayesian estimates. Major topics include: The likelihood principle Decision theory/bayes rules Shrinkage estimators Frequentist
More informationRussian Journal of Agricultural and Socio-Economic Sciences, 3(15)
ON THE COMPARISON OF BAYESIAN INFORMATION CRITERION AND DRAPER S INFORMATION CRITERION IN SELECTION OF AN ASYMMETRIC PRICE RELATIONSHIP: BOOTSTRAP SIMULATION RESULTS Henry de-graft Acquah, Senior Lecturer
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationTechnical Specifications
Technical Specifications In order to provide summary information across a set of exercises, all tests must employ some form of scoring models. The most familiar of these scoring models is the one typically
More informationPSYCH-GA.2211/NEURL-GA.2201 Fall 2016 Mathematical Tools for Cognitive and Neural Science. Homework 5
PSYCH-GA.2211/NEURL-GA.2201 Fall 2016 Mathematical Tools for Cognitive and Neural Science Homework 5 Due: 21 Dec 2016 (late homeworks penalized 10% per day) See the course web site for submission details.
More informationA Comparison of Robust and Nonparametric Estimators Under the Simple Linear Regression Model
Nevitt & Tam A Comparison of Robust and Nonparametric Estimators Under the Simple Linear Regression Model Jonathan Nevitt, University of Maryland, College Park Hak P. Tam, National Taiwan Normal University
More informationSample Size Considerations. Todd Alonzo, PhD
Sample Size Considerations Todd Alonzo, PhD 1 Thanks to Nancy Obuchowski for the original version of this presentation. 2 Why do Sample Size Calculations? 1. To minimize the risk of making the wrong conclusion
More informationCLINICAL TRIAL SIMULATION & ANALYSIS
1 CLINICAL TRIAL SIMULATION & ANALYSIS Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand NHG Holford, 217, all rights reserved. 2 SIMULATION Visualise the expected
More informationAdvanced IPD meta-analysis methods for observational studies
Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)
More informationSpeaker: Clement Ma, PhD, Dana-Farber/Boston Children s Cancer and Blood Disorders Center, Harvard Medical School
October 24 2017 Speaker: Clement Ma, PhD, Dana-Farber/Boston Children s Cancer and Blood Disorders Center, Harvard Medical School Dr. Clement Ma is Lead Biostatistician at Dana-Farber/Boston Children s
More informationEcological Statistics
A Primer of Ecological Statistics Second Edition Nicholas J. Gotelli University of Vermont Aaron M. Ellison Harvard Forest Sinauer Associates, Inc. Publishers Sunderland, Massachusetts U.S.A. Brief Contents
More informationMissing data. Patrick Breheny. April 23. Introduction Missing response data Missing covariate data
Missing data Patrick Breheny April 3 Patrick Breheny BST 71: Bayesian Modeling in Biostatistics 1/39 Our final topic for the semester is missing data Missing data is very common in practice, and can occur
More informationComparing Two ROC Curves Independent Groups Design
Chapter 548 Comparing Two ROC Curves Independent Groups Design Introduction This procedure is used to compare two ROC curves generated from data from two independent groups. In addition to producing a
More informationClinical trials with incomplete daily diary data
Clinical trials with incomplete daily diary data N. Thomas 1, O. Harel 2, and R. Little 3 1 Pfizer Inc 2 University of Connecticut 3 University of Michigan BASS, 2015 Thomas, Harel, Little (Pfizer) Clinical
More informationProfile Analysis. Intro and Assumptions Psy 524 Andrew Ainsworth
Profile Analysis Intro and Assumptions Psy 524 Andrew Ainsworth Profile Analysis Profile analysis is the repeated measures extension of MANOVA where a set of DVs are commensurate (on the same scale). Profile
More informationDr. Kelly Bradley Final Exam Summer {2 points} Name
{2 points} Name You MUST work alone no tutors; no help from classmates. Email me or see me with questions. You will receive a score of 0 if this rule is violated. This exam is being scored out of 00 points.
More informationNonparametric DIF. Bruno D. Zumbo and Petronilla M. Witarsa University of British Columbia
Nonparametric DIF Nonparametric IRT Methodology For Detecting DIF In Moderate-To-Small Scale Measurement: Operating Characteristics And A Comparison With The Mantel Haenszel Bruno D. Zumbo and Petronilla
More informationHS Exam 1 -- March 9, 2006
Please write your name on the back. Don t forget! Part A: Short answer, multiple choice, and true or false questions. No use of calculators, notes, lab workbooks, cell phones, neighbors, brain implants,
More informationKnowledge is Power: The Basics of SAS Proc Power
ABSTRACT Knowledge is Power: The Basics of SAS Proc Power Elaina Gates, California Polytechnic State University, San Luis Obispo There are many statistics applications where it is important to understand
More informationMultivariate Regression with Small Samples: A Comparison of Estimation Methods W. Holmes Finch Maria E. Hernández Finch Ball State University
Multivariate Regression with Small Samples: A Comparison of Estimation Methods W. Holmes Finch Maria E. Hernández Finch Ball State University High dimensional multivariate data, where the number of variables
More informationA Brief (very brief) Overview of Biostatistics. Jody Kreiman, PhD Bureau of Glottal Affairs
A Brief (very brief) Overview of Biostatistics Jody Kreiman, PhD Bureau of Glottal Affairs What We ll Cover Fundamentals of measurement Parametric versus nonparametric tests Descriptive versus inferential
More informationReflection Questions for Math 58B
Reflection Questions for Math 58B Johanna Hardin Spring 2017 Chapter 1, Section 1 binomial probabilities 1. What is a p-value? 2. What is the difference between a one- and two-sided hypothesis? 3. What
More informationA Bayesian Measurement Model of Political Support for Endorsement Experiments, with Application to the Militant Groups in Pakistan
A Bayesian Measurement Model of Political Support for Endorsement Experiments, with Application to the Militant Groups in Pakistan Kosuke Imai Princeton University Joint work with Will Bullock and Jacob
More information